Application of Phage Display Technology in the Development of Antibodies
A special issue of Antibodies (ISSN 2073-4468). This special issue belongs to the section "Antibody Discovery and Engineering".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 1534
Special Issue Editor
Special Issue Information
Dear Colleagues,
It has been more than three decades since muromonab-CD3, the first monoclonal antibody, was approved by the United States Food and Drug Administration (US FDA), back in 1986. Since then, the field of monoclonal antibodies has grown exponentially, with the achievement of the latest milestone of the 100th approved antibody product.
However, the role of antibodies, especially monoclonal antibodies, transcends just the field of therapy but also diagnostics, with the latter being established much earlier with the inception of hybridoma technology. The hybridoma approach, although providing good-affinity monoclonal antibodies, suffered from immunological shortcomings when applied to humans.
It was not until phage display technology was introduced that fully human monoclonal antibodies were a reality. The advent of phage display brought about an influx of antibody derivatives, not limited to just human antibodies but also allowing the introduction, research, and application of other antibody formats. The approach allowed for recombinant versions of traditional mouse and rabbit antibodies to be generated in vitro together with other species, such as camelids, sharks, bovines, and macaques.
As the application of monoclonal antibodies is widespread, the goal of this Special Issue is to highlight the broad-reaching scope of phage-display-derived antibodies, from research to diagnostics and therapy. This includes different antibody formats of different origins for various indications.
Dr. Theam Soon Lim
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- phage display
- monoclonal antibodies
- immunotherapy
- immunodiagnostics
- infectious diseases
- communicable diseases
- non-communicable diseases
- directed evolution
- affinity maturation
- antibody engineering
